MLTX (MoonLake Immunotherapeutics AG) Earnings per share for the last four quarters

MoonLake Pharma (MLTX) - corporate logo

MoonLake Immunotherapeutics (MLTX) is a promising biotech company with high trust from physicians and patients. The rolling annual growth rate of net income per share visualizes the dynamics of this success, where -10.30 determines the current level of this parameter. Strategic partnerships in antibody development enhance the asset's investment attractiveness. Innovative treatment methods for autoimmune pathologies allow the company to compete solely on the basis of scientific achievements.

MLTX moonlaketx.com Net earnings per share (EPS TTM) (02/11/2024 - 11/18/2026)

MLTX (MoonLake Immunotherapeutics): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:MLTX (MoonLake Immunotherapeutics AG)
Core merchandise of MoonLake Corp

Institutional capital evaluates the potential of MoonLake Immunotherapeutics (MLTX) through the lens of the scalability of its unique nanobody ecosystem for inflammation therapy. By analyzing the annual net income per share TTM growth trend, investors can track EPS dynamics over a rolling year, allowing them to verify the asset's financial stability and determine an entry point without the risk of buying at peaks.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS